#  Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop IRD Treatment 

 





July 09, 2020

 

 

 Massachusetts Eye and Ear is entering into an exclusive licensing agreement with Biogen to develop a potential treatment for inherited retinal degeneration due to mutations in the *PRPF31* gene, which are among the most common cause for autosomal dominant retinitis pigmentosa.

Previous lab-based research performed by members of the Harvard Ophthalmology Ocular Genomics Institute, led by [Eric A. Pierce, MD, PhD](/ericpierce), the William F. Chatlos Professor of Ophthalmology at Harvard Medical School, demonstrated that adeno-associated, virus-mediated gene augmentation therapy for *PRPF31* can restore normal function to *PRPF31* mutant RPE cells. Biogen will build upon this prior work and conduct the studies needed for clinical development of *PRPF31* gene therapy. [Read the press release](https://masseyeandear.org/news/press-releases/2020/07/mass-eye-and-ear-enters-licensing-agreement-with-biogen)

 

 

 



 

 See also:- [ Eric Pierce, MD, PhD ](/news-categories/ericpierce)
 
 

 Share on:- [     Facebook ](#)
- [     Twitter ](#)
- [     Linkedin ](#)